Previous 10 | Next 10 |
2023-05-11 09:29:59 ET More economic data, earnings reports, performance outlooks from management teams, and the Federal Reserve are driving sentiment in the stock market today. Whether you’re trading penny stocks or higher-priced company shares, there’s no getting around ...
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for focal epilepsy Cash and investments of $85.8 million as of March ...
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider than current market leader based on MES model Phase 1 results support preclinical profile ...
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...
2023-04-17 15:24:51 ET Thanks to an explosion of interest in penny stocks , plenty of stocks under $5 are gaining momentum in the stock market today. Whether you’re looking for short squeeze stocks, low float stocks, or simply hunting for a list of penny stocks in a specific sect...
BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...
2023-04-10 03:24:51 ET Summary Praxis Precision Medicines' ulixacaltamide (PRAX-944) fails to achieve statistical significance in primary endpoint for essential tremor treatment in Phase 2 clinical trial. The drug demonstrates nominal statistical significance in secondary endpoint...
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...
Gainers: Altamira Therapeutics ( CYTO ) +86% . Bullfrog AI ( BFRG ) +26% . Seer ( SEER ) +25% . Ardelyx ( ARDX ) +23% . Lucy Scientific Discovery ( LSDI ) +16% . Losers: Praxis Precision Medicines ( PRAX ) -55% . Veru (...
Praxis Precision Medicines PRAX -49% after mid-stage data for movement disorder candidate . Veru VERU -34% after Veru COVID respiratory treatment sabizabulin declined authorization by FDA . Cidara Therapeutics ( CDTX ) -17% on launching concurrent but separa...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-07-26 13:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...